On June 5, 2026, Marcus Gail Boxer, serving as a director at Natera, Inc. (NASDAQ:NTRA), executed a series of transactions involving the company's common equity. The director sold approximately $2.39 million worth of shares, specifically 11,000 units, following the exercise of stock options for an identical number of shares. The transaction took place as the stock closed at $222.83 on that date. Market analysis from InvestingPro indicates that Natera is currently trading above its Fair Value estimate, categorizing it among overvalued equities within the healthcare sector.
The sale of common stock was not executed as a single block but occurred through multiple transactions. The price per share varied during this period, ranging from $216.0631 to $218.815. The aggregate value realized from these specific sales amounted to $2,389,328. Prior to executing the sales earlier on the same day, Boxer acquired 11,000 shares of Natera common stock. This acquisition was facilitated by exercising stock options at a price of $22.83 per share, resulting in a total acquisition value of $251,129. These particular stock options were fully exercisable and are set to expire on May 23, 2029.
Following the completion of these transactions, Marcus Gail Boxer directly holds 6,183 shares of Natera common stock. The company, which currently carries a market capitalization of $31.67 billion, has delivered a return of 34.86% over the past year. Investors seeking deeper insights into Natera's valuation and growth prospects can access a comprehensive Pro Research Report, available for this equity and over 1,400 other US equities on InvestingPro.
In parallel with the insider activity, Natera has reported several significant developments within its operational landscape. Wolfe Research recently initiated coverage on Natera, assigning an outperform rating and establishing a price target of $260. This rating reflects confidence in the company's market leadership regarding molecular residual disease testing. Concurrently, Goldman Sachs began coverage with a Neutral rating and a price target of $245, citing Natera's strong commercial execution and clinical data.
Furthermore, Natera announced an enhancement to its Panorama non-invasive prenatal test. This update aims to reduce the no-call rate to 0.5% by utilizing advanced sequencing technology. The company also entered into a partnership with Diakonos Oncology Corp. for a trial designed to assess molecular response in melanoma patients using its Signatera test. Additionally, Natera appointed Thomas Lynch and Eric Rubin, both seasoned oncology experts, to its board of directors. These developments indicate ongoing strategic initiatives and potential growth avenues for Natera.